| Schedule of Segment Reporting Information, by Segment |
The following table summarizes the segment's financial information including the Company’s significant segment expenses: | | | | | | | | | | | | | Three Months Ended
March 31, | | 2025 | | 2024 | | Revenue: | | | | | | | | | | | | | Royalty revenue | $ | 25,427 | | | $ | 9,302 | | | Total revenue | 25,427 | | | 9,302 | | | Segment operating expenses: | | | | | Research and development: | | | | | Direct program costs: | | | | | Ovaprene | 1,495,727 | | | 2,183,873 | | | Sildenafil Cream, 3.6% | 211,389 | | | 460,107 | | | Other advanced clinical stage programs | 490,562 | | | 446,671 | | | Phase 1 and Phase 1-ready clinical stage programs | 496,747 | | | 229,550 | | | Preclinical stage programs | 1,098,738 | | | 1,371,708 | | | Other development programs | — | | | 12,794 | | | Contra-R&D expenses | (2,618,373) | | | (2,652,715) | | | Total research and development direct program costs | 1,174,790 | | | 2,051,988 | | | Indirect costs: | | | | | Personnel-related (including stock compensation) | 1,492,248 | | | 1,482,597 | | | Other indirect costs | 78,735 | | | 78,199 | | | Contra R&D expenses | (448,392) | | | (259,264) | | | Total research and development indirect costs | 1,122,591 | | | 1,301,532 | | | General and administrative | 2,309,164 | | | 2,670,581 | | | Other operating expenses | — | | | 7,674 | | | Total segment operating expenses | 4,606,545 | | | 6,031,775 | | | Loss from operations | (4,581,118) | | | (6,022,473) | | | | | | | Interest expense | 134,050 | | | 209,138 | | | Interest income | (156,621) | | | (88,133) | | | Other income (expense), net | 180,240 | | | (611,878) | | | Net loss | $ | (4,378,307) | | | $ | (6,755,356) | |
|